Skip to main content
TNGX logo

TNGX · Tango Therapeutics, Inc. · Documents

Track TNGX — free
$21.93 -0.78 (-3.43%)
Market Cap
$3.85B
Shares
169.46M
Volume · Nov 20 932.36K Avg daily vol (3M) 3.41M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $62.38M up 48.3% 10-K filed Mar 5, 2026 Quarterly report FY2026 Q3 Revenue $0 10-Q filed Nov 9, 2026 Latest results 82% ORR supports planned Phase 3 daraxonrasib combination trial 8-K filed Nov 9, 2026
2026
Nov 10
Investor event
Frontline pancreatic study planned

Tango Therapeutics plans to begin a frontline pancreatic cancer phase three study in the first half of next year, enrolling 240 patients in each arm with response rate and progression-free survival as dual primary endpoints.

3 source passages
I'm with Tango Therapeutics this morning. At ESMO we disclosed our plan to start a frontline study. A phase three study in front-line pancreatic cancer in the first half of next year. The study we suggested to FDA was a one-to-one randomized clinical trial of 240 patients in each arm. We are proposing, and FDA was fully in line with this, response rate and progression-free survival as dual primary endpoints. Open the document at this passage
Nov 9
Current report 8-K
82% ORR supports planned Phase 3 daraxonrasib combination trial

Tango Therapeutics reported 82% ORR and 88% PFS for vopimetostat plus daraxonrasib in pancreatic cancer, plans Phase 3 in first half of 2027, and held $977.5 million in cash, cash equivalents and marketable securities at September 30, 2026.

Financial results
5 source passages
Data demonstrated that vopimetostat in combination with daraxonrasib achieved an 82% objective response rate (ORR) and 88% nine-month progression-free survival (PFS) rate in efficacy evaluable patients with second and third line pancreatic ductal adenocarcinoma (PDAC), and median PFS was not yet reached. Based upon the encouraging Phase 1/2 data and discussions with the US Food and Drug Administration (FDA), Tango intends to initiate a pivotal Phase 3 study of the combination of vopimetostat plus daraxonrasib in front-line MTAP-deleted pancreatic cancer. The Company plans to initiate the study in the first half of 2027. As of September 30, 2026, the Company held $977.5 million in cash, cash equivalents and marketable securities, which the Company expects to fund its current operating plan. Tango Therapeutics, Inc. (NASDAQ: TNGX) a clinical-stage biotechnology company committed to delivering breakthrough targeted therapies that extend and improve the lives of patients with cancer, today reported financial results for the third quarter ended September 30, 2026, and provided business highlights. Open the document at this passage
Nov 9
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Combination shows 82% ORR, plans registrational trial

Tango Therapeutics reported an 82% ORR for vopimetostat plus daraxonrasib in 22 efficacy-evaluable patients with MTAP-deleted/RAS-mutant PDAC and plans a global, randomized registrational trial in first-line PDAC in the first half of 2027.

Revenue $0 Net loss $68.39M Diluted EPS -$0.39
Read from the MD&A section
4 source passages
Tango was founded with a clear mission: to discover the next wave of targeted therapies in oncology by addressing the specific genetic alterations that drive cancer. In efficacy-evaluable PDAC patients with MTAP-deleted, RAS-mutant PDAC, we observed an ORR of 82% (18 of 22 patients, with 11 of 18 cPRs and 7 unconfirmed partial responses), an 88% 9-month PDF rate and a 100% DCR. Following recent interactions with the FDA, we plan to initiate a global, randomized registrational trial evaluating the combination of vopimetostat with daraxonrasib in front-line patients with MTAP-deleted PDAC. We anticipate initiating this study in the first half of 2027. Open the document at this passage
Oct 23
Investor event
Combination shows 82% response rate; Phase III planned for 2027

Tango's updated data for vopametistat with Diracxon RASIB in pancreatic cancer show an objective response rate of 82% among 22 patients with metastatic pancreatic cancer and a nine-month progression-free survival rate of 88%. The company plans to start a Phase III study in first-line MTAP-deleted pancreatic cancer, anticipated to enroll 484 patients, in the first half of 2027. It also plans to start a study in MTAP wild-type pancreatic cancer in the first half of 2027.

5 source passages
among the 22 patients with metastatic pancreatic cancer, the objective response rate was 82% The nine-month landmark PFS rate is 88% In the first half of 2027, we intend to launch a pivotal study in patients with MTAP-deleted pancreatic cancer in the frontline setting. The study is anticipated to enroll 484 patients. In the first half of 2027, we intend to evaluate VOCA metastat in combination with a PAN-RAS inhibitor in approximately 25 to 30 patients with mTAP wild-type pancreatic cancer Open the document at this passage
Oct 23
Current report 8-K
Vopimetostat Combination Shows 82% Response Rate in Pancreatic Cancer

Tango Therapeutics reported an 82% objective response rate for vopimetostat plus daraxonrasib in 22 efficacy-evaluable patients with second line or third line MTAP-deleted/RAS-mutant pancreatic cancer. It plans to start a randomized registrational trial in front-line MTAP-deleted pancreatic cancer in the first half of 2027. It also intends to reduce its workforce by approximately 14% as part of a strategic reprioritization.

Regulation FD disclosure, Other events Read from the first part of this long document
3 source passages
updated data from the ongoing Phase 1/2 study demonstrated an 82% objective response rate (“ORR”), median progression-free survival (“PFS”) not yet reached, and a 9-month PFS rate of 88% in 22 patients with second line or third line MTAP-deleted/RAS-mutant PDAC who were efficacy-evaluable. The Company anticipates initiating this study in the first half of 2027. the Company intends to reduce its overall workforce by approximately 14%, with the majority of the headcount reductions from the Company’s research group. Open the document at this passage
Aug 11
Current report 8-K
Other events AI summary on its way
Aug 11
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $0 Net loss $55.34M Diluted EPS -$0.37
May 13
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $0 Net loss $45.51M Diluted EPS -$0.32
Mar 5
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $62.38M ▲ 48.3% Net loss $101.59M Diluted EPS -$0.87
2025
Feb 27
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $42.07M ▲ 15.2% Net loss $130.3M Diluted EPS -$1.19
2024
Showing 1–50 of 108 documents
Key facts CIK 1819133 CUSIP 87583X109 13F (30d) 267 filings 250 filers Visit website Investor relations